HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
- Written by PR Newswire
![]() |
- HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.
- HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology, targeting ophthalmic and otic diseases.
- Progress...
Read more: HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update















